23 May 2013
Keywords: celltech, royalties, news, receive, sales, reopro, abciximab
Article | 20 February 1995
- Celltech is to receive royalties on the sales of ReoPro
(abciximab), an antibody-based drug licensed from Centocor and launched
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
20 February 1995
© 2013 thepharmaletter.com